$1.15 Billion

Guardant Health Inc.

Convertible Debt

Co-Manager, November 2020

Guardant Health Inc.

Guardant Health, Inc. is a leading molecular diagnostics company focused on enabling precision medicine through use of its proprietary blood-based assays, focused in the emerging liquid biopsy arena. The Company’s core Health Oncology Platform is designed to improve patient clinical outcomes, lower healthcare costs, and accelerate biopharmaceutical drug development to manage cancer across all stages of the disease — targeting a >$35 billion total addressable market. The Company’s platform is designed to address a major challenge in oncology: the limitations and time / cost intensity inherent to a tissue-based diagnostic approach.

More Like This

Jan 2021
$69 Million

Convertible Notes Restructuring

Exclusive Financial Advisor

View Details >
Nov 2020
$197 Million
Tilray Logo

Convertible Notes Exchange

Exclusive Financial Advisor

View Details >
May 2020
$200 Million

Convertible Debt

Co-Manager

View Details >